Date: 2011-12-21
Type of information:
Compound: stable aqueous or higher concentration formulations of emerging protein and peptide drug candidates developed by Lilly
Company: Arecor (UK) Eli Lilly (USA)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: Arecor Limited has entered into a collaboration agreement with Eli Lilly and Company to assess Arecor’s advanced protein formulation technologies for possible use with Lilly’s growing pipeline of biological–based drugs. Under this agreement, Arecor will develop stable aqueous or higher concentration formulations of emerging protein and peptide drug candidates developed by Lilly. In addition, Arecor will work with Lilly to potentially offer improved formulations of Lilly’s existing therapeutic proteins in several therapeutic areas.
Arecor Limited was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into interactions between proteins and their immediate environment. Proteins and vaccines are often fragile entities, and stability can represent significant constraints in the development of new products and extending the use of existing products. Arecor has developed Arestat™, a patented set of tools for stabilization which address the main pathways of degradation. As a simple reformulation, Arestat™ can be readily incorporated into standard manufacturing practice, without covalent modification of the biologic and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines.
Financial terms:
Latest news:
